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Background: The diagnosis of childhood asthma covers a broad spectrum of pathological mechanisms that can
lead to similarly presenting clinical symptoms, but may nonetheless require different treatment approaches. Distinct
underlying inflammatory patterns are thought to influence responsiveness to standard asthma medication.
Methods/design: The purpose of the PACMAN2 study is to identify inflammatory phenotypes that can discriminate
uncontrolled childhood asthma from controlled childhood asthma by measures in peripheral blood and exhaled air.
PACMAN2 is a nested, case–control follow-up study to the ongoing pharmacy-based “Pharmacogenetics of Asthma
medication in Children: Medication with Anti-inflammatory effects” (PACMAN) study. The original PACMAN cohort
consists of children aged 4–12 years with reported use of asthma medication. The PACMAN2 study will be
conducted within the larger PACMAN cohort, and will focus on detailed phenotyping of a subset of the PACMAN
children. The selected participants will be invited to a follow-up visit in a clinical setting at least six months after
their baseline visit based on their adherence to usage of inhaled corticosteroids, their asthma symptoms in the past
year, and their age (≥ 8 years). During the follow-up visit, current and long-term asthma symptoms, medication use,
environmental factors, medication adherence and levels of exhaled nitric oxide will be reassessed. The following
measures will also be examined: pulmonary function, exhaled volatile organic compounds, as well as inflammatory
markers in peripheral blood and blood plasma. Comparative analysis and cluster-analyses will be used to identify
markers that differentiate children with uncontrolled asthma despite their use of inhaled corticosteroids (ICS) (cases)
from children whose asthma is controlled by the use of ICS (controls).
Discussion: Asthmatic children with distinct inflammatory phenotypes may respond differently to anti-
inflammatory therapy. Therefore, by identifying inflammatory phenotypes in children with the PACMAN2 study, we
may greatly impact future personalised treatment strategies, uncover new leads for therapeutic targets and improve
the design of future clinical studies in the assessment of the efficacy of novel therapeutics.
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Asthma is one of the most common chronic diseases in
childhood [1]. It is increasingly recognized that asthma
is not a homogeneous disease and that different patho-
logical mechanisms can lead to the clinical expression of
asthma [2]. Inhaled corticosteroids (ICS) have become
the first-line controller therapy for asthma, and the
standard treatment of persistent asthma is generally
guided by symptom control [1]. Most children with per-
sistent asthma symptoms will have a beneficial response
to ICS. Nevertheless, there is large inter-individual vari-
ability [3] and a portion of children with asthma will re-
main uncontrolled despite intensive treatment with high
dosages of inhaled corticosteroids and/or oral corticoste-
roids. Uncontrolled asthma leads to a lower quality of
life, may induce lung damage, can cause life-threatening
exacerbations and results in increased healthcare re-
sources utilization and expenditures [4]. Therefore, it is
essential to identify asthmatic children with a high risk
of poor response to standard asthma medication at an
early stage.
A poor treatment response to ICS can be caused by
various factors, including poor therapy adherence, mis-
diagnosis or continued exposure to allergens [5]. In ad-
dition, biological factors, including genetic variations,
seem to play an important role in inter-individual ICS re-
sponsiveness. A recent study by Tantisira et al. showed
that asthma patients with a single-nucleotide polymorph-
ism (SNP) in the gene GLCCI1 have a worse response in
lung function upon ICS treatment [6]. Furthermore, a
SNP in the FCER2 receptor gene has been associated with
an increased risk of asthma-related hospital visits, uncon-
trolled asthma and higher daily steroid dosages [7,8].
Nevertheless, despite the progress in asthma pharmaco-
genetic research, only a small percentage of the variability
in treatment response can currently be explained by varia-
tions in SNPs.
In addition to genetic polymorphisms, other biological
factors such as distinct inflammatory patterns may influ-
ence ICS responsiveness. Inflammation in asthma is
often described as ‘eosinophilic’, based upon the pres-
ence of primed eosinophils in the airways. However, it
has been shown that airway inflammation in asthmatic
patients may also occur in the absence of increased
levels of eosinophils and in the presence or absence of
neutrophilia [9,10]. Corticosteroids induce cell death in
eosinophils, but can induce survival in other immune
cells such as neutrophils [11]. Therefore, it is likely that
asthmatic patients with distinct inflammatory pheno-
types may vary in their response to corticosteroids. This
has been confirmed by various studies showing that
asthmatic patients with non-eosinophilic inflammation
have a less beneficial response to corticosteroids when
compared to those with eosinophilic inflammation [12].In addition, a RCT carried out by Green and colleagues
showed that titrating ICS treatment based on sputum
eosinophilia led to better asthma control compared to ti-
trating treatment based on standard asthma guidelines
in adults without a significant difference in corticoster-
oid usage [13]. A cluster analysis by Haldar et al. showed
that titrating treatment based on sputum eosinophilia to
prevent exacerbations was superior in two clusters of pa-
tients (specifically refractory asthma) where markers of
eosinophilic inflammation were discordant with the
presence of asthma symptoms [2]. A recent RCT in
severe asthmatic children found no differences in exac-
erbations or improvement of asthma control when treat-
ment was adjusted based on sputum eosinophilia [14].
Various surrogate markers for airway inflammation
have been described, including fraction of nitric oxide in
exhaled breath (FeNO), volatile organic compounds
(VOCs) in exhaled breath, sputum eosinophil counts
and serum eosinophil cationic protein. Although these
are, to a certain extent, applicable in clinical practice,
few studies have assessed whether these markers are as-
sociated with ICS response in children [12]. In the
PACMAN2 study we will focus on inflammatory pheno-
types that may distinguish children who despite ICS use
continue to suffer from asthma symptoms from children
who are well controlled on ICS treatment. We aim to
integrate clinical, proteomic, cellular and breath meta-
bolomic data in order to more accurately define inflam-
matory mechanisms underlying asthma in children.
PACMAN2 is an exploratory follow-up study of the
ongoing Pharmacogenetics of Asthma medication in




PACMAN2 is a nested case–control study within
the observational pharmacy-based PACMAN cohort.
PACMAN is an ongoing, cross-sectional study, includ-
ing children aged 4–12 years with reported use of
asthma medication. The inclusion criteria requires that
they have had ≥3 prescriptions for Anatomical
Therapeutic Chemical (ATC) code R03 medication in
the past 2 years, including ≥1 prescription for R03
medication in the past 6 months. ATC code R03 medi-
cations are drugs prescribed for obstructive airway dis-
eases and are comprised of short-acting beta-2 agonists,
long-acting beta-2 agonists and inhaled corticosteroids
(http://www.whocc.no/atc_ddd_index/?code=R03). In-
clusion of children in the PACMAN cohort started in
April 2009 and is still currently ongoing with over 990
children having been included thus far. Details of the
study protocol of the PACMAN cohort study have been
described elsewhere [15].
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included in the PACMAN cohort (PACMAN) will be se-
lected for a follow-up visit in a clinical setting. This visit
will be planned for at least six months after the original
baseline visit and will include the reassessment of asthma
symptoms, medication use, adherence to ICS and levels of
FeNO. Furthermore, additional measurements will be
made including pulmonary function testing and the meas-
urement of exhaled volatile organic compounds in exhaled
breath and inflammatory markers in peripheral blood by
immunophenotyping and proteomics approaches. Com-
parative analyses and cluster-analyses will be used to
identify markers that discriminate children with uncon-
trolled asthma despite ICS use (cases) from children with
controlled asthma on ICS (controls). Cases and controls
will be classified according to current and long-term
asthma control at the time of the follow-up study visit, as
this is most likely to reflect their current disease state.
Current, uncontrolled childhood asthma despite ICS
usage will be the primary study endpoint.
Figure 1 presents a flowchart of the PACMAN study
and the follow-up (PACMAN2).
Selection of study subjects
Children in PACMAN2 will be selected from the
PACMAN cohort based on the inclusion criteria shown
in Table 1. In order to increase the probability of includ-
ing both children with long-term well controlled and
long-term poorly controlled asthma, children will be
selected from the PACMAN cohort based on the
following:
 The child’s asthma is classified as long-term
controlled or long-term uncontrolled (see section
below) at baseline, and
 The child is adhering to his/her inhaled
corticosteroid regimen (Medication Adherence
Rating Scale ≥ 21 [16]) at baseline.
Current use of ICS will be checked when children are
invited to participate in the follow-up study visit. Long-
term and current asthma control will be reassessed dur-
ing the follow-up study visit, as this may have changed
over time. In the primary analysis we will compare chil-
dren that are currently uncontrolled despite ICS usage
at the time of the follow-up study to children whose
asthma is controlled by the use of ICS at the time of the
follow-up study.
Current asthma control
Current asthma control will be assessed at both the
baseline study visit and the follow-up study visit using
the 6-item version of the Asthma Control Questionnaire
(ACQ) (symptoms plus rescue medication use) [17]. AnACQ-score of < 0.75 will be considered as ‘well con-
trolled asthma’, a score ≥ 0.75 will be considered ‘poorly
controlled asthma’.
Long-term asthma control
The definition of long-term asthma control is based on
the guidelines of the Global Initiative for Asthma [1].
During the baseline study visit and the follow-up study
visit, parents will be asked to score the presence of and
frequency of the following asthma symptoms: 1) daytime
symptoms (wheezing, coughing, and shortness of breath),
2) nighttime symptoms, 3) limitations in daily activities,
and 4) use of rescue medication during all four seasons of
the previous year. Using this data, the children’s asthma
will be classified using the following definitions. Long-
term, uncontrolled asthma is defined as ≥ 3 seasons of un-
controlled asthma in the past year with a season being
considered uncontrolled when ≥ 3 asthma symptoms
(daytime symptoms, daytime limitations, nighttime limita-
tions or use of co-medication) occur on a daily or weekly
basis [18]. Long-term controlled asthma is defined as ≥ 3
seasons of controlled asthma in the past year. A season is
considered to be ‘controlled’ when asthma symptoms do
not occur or occur less than weekly. In addition, children
whose asthma is defined as long-term, controlled during
the past year, but who reported the use of oral corticoste-
roids (OCS) or asthma-related ER visit(s) in the past year
will be excluded.
Data collection PACMAN2
Children and their parents selected from the PACMAN
cohort will be invited to a study visit at the Wilhelmina
Children’s Hospital. During this visit, data will be col-
lected through the use of questionnaires and the mea-
surements of lung function, exhaled breath, peripheral
blood and blood plasma. Table 2 lists the instruments
being used during the baseline visit (PACMAN) and the
follow-up (PACMAN2).
Electronic portal
Before the scheduled follow-up visit, children and par-
ents will be asked to complete an extensive online ques-
tionnaire regarding the child’s general health, respiratory
symptoms, respiratory infections, hay fever, food allergy,
eczema, as well as environmental factors. The online
questionnaire is located in a patient portal (‘The Elec-
tronic Portal for children with respiratory and allergic
symptoms’) developed by the Wilhelmina Children’s
Hospital. The rationale and design of the Electronic Por-
tal has been previously published [33].
In order to screen for the presence of atopic diseases,
parents and children will be asked to answer screening
questions based on the core questions of the Inter-














Letter to General Practitioner to request 
information on asthma diagnosis and 
referral to specialist
Parents and child receive questionnaire 
periodically (ACT and MARS) through 
Electronic Portal 
Exclusion based on:
age (< 8 years)
No ICS use
Not adherent to ICS
Partially controlled asthma
No consent to be approached
for future research
Figure 1 Flow chart data collection PACMAN cohort study and follow up.
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pants will then be prompted by the system to complete
additional disease-topic specific questionnaires including
the Asthma Control Test (ACT) [35], the Medication
Adherence Rating Scale (MARS) [16] and the PaediatricAsthma Quality of Life Questionnaire (PAQLQ) [23].
The online questionnaire also contains questions on en-
vironmental factors such as tobacco smoke exposure,
pet exposure and living environment. Additionally, after
the follow-up study visit, parents and children will
Table 1 Inclusion criteria PACMAN2 study
Long-term uncontrolled Long-term controlled
• Parental consent to be approached for future research • Parental consent to be approached for future research
• 8 years of age or older • 8 years of age or older
• Current ICS user • Current ICS user
• Adherent to corticosteroids (MARS≥21)‡ • Adherent to corticosteroids (MARS≥21)‡
• Long-term uncontrolled in the past year‡ • Long-term controlled asthma in the past year‡
≥ 3 seasons in the past year in which symptoms were uncontrolled: ≥ 3 seasons in the past year in which symptoms were controlled:
o ≥ 3 of the following symptoms (daily or weekly) o Following symptoms are not present or occur less than weekly:
▪ Daytime asthma symptoms (cough, wheeze, shortness of breath) ▪ Daytime asthma symptoms (cough, wheeze, shortness of breath)
▪ Nighttime asthma symptoms ▪ Nighttime asthma symptoms
▪ Limitations in daily activities ▪ Limitations in daily activities
▪ Rescue medication use ▪ Rescue medication use
• No asthma-related ER visit in the past year‡
• No OCS use in the past year‡
‡ Based on the retrospective questionnaire data obtained during the PACMAN pharmacy study visit (baseline). Current ICS use was confirmed during telephone
contact prior to the follow up study visit. ICS Inhaled Corticosteroids, MARS Medication Adherence Report Scale, OCS Oral Corticosteroids, ER Emergency Room.
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child’s current asthma symptoms and use of medication
during each season (every three months).
Additional questionnaire
In addition to the Electronic Portal questionnaires, par-
ents and children will be asked to complete an additional,
short questionnaire during their follow-up visit. This
questionnaire will include the asthma control question-
naire (ACQ) [19] to assess asthma control in the previous
week, questions regarding asthma symptoms during the
previous seasons (to assess long-term asthma control), as
well as questions about asthma-related health care utili-
zation, recent severe exacerbations (OCS use, asthma-
related ER visits and hospitalisation) and current asthma
medication use.
Lung function measurements and FeNO
Trained lung function technicians will perform spirom-
etry and FeNO measurements. A single-breath, on-line
measurement of FeNO will be carried out with a hand-
held electrochemical analyser (NIOX Mino, Aerocrine,
Solna, Sweden). FeNO is measured during the baseline
visit in a similar manner. Lung function measurements
will include: forced expiratory volume in one second
(FEV1), forced vital capacity (FVC), and FEV1/FVC ratios
before and after the inhalation of 800 μg salbutamol.
Volatile organic compounds (VOCs) in exhaled breath
VOCs will be measured according to a validated method
described previously [36]. In short, while wearing a
nose-clip, children will be asked to breathe normally for
5 minutes through a three-way, non-rebreathing valve
with a VOC filter (A2, North Safety, Middelburg, theNetherlands) at the inspiration port and a silica filter at
the expiration port. Then, after taking a maximal deep
inspiration, the child will be asked to exhale a single,
vital capacity volume into a Tedlar bag connected to the
expiration port and a silica reservoir to dry the exhaled
air. The VOCs present in at least 500 ml of exhaled air
in the Tedlar bag will be captured in Tenax GR Tubes
(Interscience, Breda, The Netherlands) by using a peri-
staltic pump. The VOCs captured in the Tenax GR
Tubes will be analysed with a validated panel of elec-
tronic noses (including carbon-poloymer, quartz micro-
balance metalloporphyrins, metal oxide sensors and ion
mobility spectrometry) in the Department of Respiratory
Medicine at the Academic Medical Centre in
Amsterdam, The Netherlands [37].IgE levels, cytokines and chemokines in peripheral blood
plasma
Levels of total and specific IgE against major allergens in
plasma will be measured according the manufacturer’s
instructions using the Phadia ImmunoCAP system
(UniCAP, Pharmacia, Sweden). These tests allow quanti-
tative measurements (in kilo antibody units per litre;
kU/l) of total IgE antibodies and specific IgE antibodies
against common respiratory allergens. A concentration
of specific IgE of 0.35 kU/l will be used as a cut-off value
for a positive test result. In addition, cytokines and
chemokines will be measured using multiplex immuno-
assay technology.Immunophenotyping of peripheral blood cells
Expression of a wide range of surface markers on periph-
eral blood cells will be determined using multi-colour flow
Table 2 Instruments used during the baseline visit (PACMAN) and follow-up study visit (PACMAN2)
Baseline visit (PACMAN) Follow-up (PACMAN2)
Questionnaires
Questions on general health, allergies, asthma and
respiratory symptoms
Questions on general health, allergies, asthma and respiratory symptoms
Asthma control (ACQ-6) [19] Asthma control (ACQ-6) [19]
- Childhood Asthma Control Test (c-ACT), Asthma Control Test (ACT) [20]§
Questions on asthma control in the past 4 seasons
[18]
Questions on asthma control in the past 4 seasons [18]
Environmental factors (passive smoking, pets, living
environment)
Environmental factors (passive smoking, pets, living environment)
Active smoking is assessed in children > 12 years of age
Beliefs about Medicines Questionnaire (BMQ) [21] -
Healthcare utilization for respiratory symptoms Healthcare utilization for respiratory symptoms
Exacerbations in the past year (ER visits/OCS usage) Exacerbations in the past year (ER visits/OCS usage)
Demographics Demographics
Current asthma medication use Current asthma medication use
Medication Adherence Rating Scale (MARS) [16] Medication Adherence Rating Scale (MARS) [16] §
- General RAND questionnaire [22]
- Growth parameters, breast feeding and vaccination status
- Paediatric Asthma Quality of Life Questionnaire (PAQLQ) [23]§
- Paediatric and Adolescent Rhinoconjunctivitis Quality of Life
Questionnaire (PRQLQ and AdolRQLQ) [24,25]§
- Allergic Rhinitis and its Impact on Asthma (ARIA) [26]§
- 6-item Otitis Media Questionnaire (OM-6) [27]§
- Brouilette Score [28] §
- Food Allergy Quality of Life Questionnaire for children and teenagers
(FAQLQ-CF and FAQLQ-TF) [29,30] §
- Self-Administered Eczema Area and Severity Index (SA-EASI) [31] §
- Children’s Dermatology Life Quality Index (CDLQI) and Infant’s Dermatitis
Quality of Life Index Questionnaire [32] §
Inhalation
technique
Inhalation technique (checklist) -
Medication history
Medication history through pharmacy system -
Lung function
Lung function testing and airway reversibility using
hand-held diagnostic spirometer
Lung function testing and airway reversibility in a clinical setting by a
trained lung function technician
Exhaled breath
Exhaled Nitric Oxide (FeNO) (Niox Mino) Exhaled Nitric Oxide (FeNO) (Niox Mino)
- Volatile Organic Compounds
Saliva
Saliva sample (Oragene) for DNA Saliva sample (Oragene) for DNA
Peripheral blood
and plasma
- Peripheral blood and plasma sample
§ In the Electronic Portal, parents and children are asked to answer ISAAC screening questions which aim to screen on the presence of atopic diseases. Based on
their initial answers, the participants will then be prompted by the system to complete additional disease-topic specific questionnaires [33].
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Netherlands). Venous blood will be collected in sterile col-
lection tubes containing sodium heparin as anticoagulant.
Shifts in activation profiles of inflammatory cells will be
assessed. The function of inflammatory cells is associated
(in part) with the activation status of the cells’ receptors,
which can be modulated upon priming with inflammatory
mediators, such as cytokines, chemokines and bacterial
products. The expression of surface markers on distinct
types of inflammatory cells will also be measured.
Proteomic profiling of peripheral blood granulocytes
in vitro treated +/− dexamethasone
The in vitro effect of corticosteroids on the protein expres-
sion of peripheral blood granulocytes will be assessed using
fluorescence 2-dimensional difference (2D) gel electro-
phoresis [38]. In brief, granulocytes will be isolated from
whole blood anticoagulated with sodium-heparin using
Ficoll-Paque. Granuloytes (5.106/mL) in incubation buffer
will be treated in vitro with dexamethasone (10-6 M) or
sham-treated with phosphate buffered saline for 15 minutes
at 37°C. Subsequently, the cells will be stimulated with
TNFα (100U/mL) for 3 hours. Cells will be lysed in lysis
buffer complemented with protease inhibitors, and pro-
teins will be precipitated with 80% acetone and dissolved
in 2D labelling buffer. 2D-DIGE technology will be used to
analyse the proteomics samples and the differential protein
expression after dexamethasone treatment. Spot detection
will be performed with DeCyder 7.0 Difference in-gel
Analysis software (GE Healthcare, Uppsala, Sweden) and
gel images will be matched using DeCyder 7.0 Biological
Variation Analysis software (GE Healthcare, Uppsala,
Sweden).
Study endpoints
We will assess whether a (combination of) inflammatory
marker(s) is (/are) associated with:
– current, uncontrolled childhood asthma despite ICS
usage (primary study endpoint).
– long-term, uncontrolled childhood asthma despite
ICS usage (secondary study endpoint).
Statistical analyses
Statistical analyses to compare controlled and uncon-
trolled asthma patients with respect to lung function,
FeNO, total and specific IgE levels and flow cytometry
data (surface and internal markers on immune cells) will
be performed using independent sample t tests or one-
way ANOVA with Dunnett’s multiple comparison test for
variables with a normal distribution, and Mann–Whitney
and Kruskall Wallis tests for variables with non-normal
distributions. In addition, unbiased cluster analysis will be
used to assess patterns of inflammation. Statistical analysisof 2D-DIGE spot intensity will be performed using
DeCyder 7.0 Extended data analysis software (GE Health-
care, Uppsala, Sweden) as described previously [38]. Since
we aim to identify a fingerprint of markers that are
differentially expressed, we will further explore the data
using principal component analysis and other clustering-
analyses on the entire data set (including VOCs data) with
adequate (cross-)validation according to recent recom-
mendation in order to limit false-discovery [39,40]. Sensi-
tivity analyses will be performed on the variables current
adherence to corticosteroid treatment and continued
exposure to environmental factors (pet exposure, passive/
active smoking).
Sample size calculation
Data concerning inflammatory markers in peripheral
blood for long-term, uncontrolled asthma in paediatric
asthma patients are lacking in the current literature;
therefore, we are not able to perform a sample size cal-
culation. However, it has been shown that proteomic
approaches can distinguish protein expression profiles of
peripheral blood cells in studies with small numbers of
asthmatic patients and controls (n≥6) [41]. Therefore,
the following sampling approach has been selected.
Based on a preliminary analysis of 744 children in-
cluded in the PACMAN cohort, we found that 86.4% of
the children use ICS and 60.2% are adherent to ICS
treatment. When we assessed long-term asthma control
at baseline, 33.4% of the children were long-term well
controlled, 53.3% of the children were long-term par-
tially controlled and 13.3% of the children were long-
term poorly controlled. We expect that approximately
5.3% (n=53) of the children in the final PACMAN popu-
lation (n=1000) will fulfil all the inclusion criteria for the
uncontrolled (adherent) asthma patients and 12.5%
(n=125) will fulfil all the inclusion criteria for the con-
trolled (adherent) asthma patients. We will therefore
invite all of the children that fulfil the inclusion criteria
of ‘uncontrolled asthma patients’, as well as an equal
number of controlled asthma patients.
Ethics
Only children whose parents consented to being ap-
proached for future research studies during their
PACMAN study visit in the pharmacy will be invited
to participate in the PACMAN2 study. A written in-
formed consent will be obtained from the parents and
from children who are ≥12 years. The Medical Ethics
Committee of the University Medical Centre Utrecht
approved this study.
Discussion
The PACMAN2 study represents an in-depth approach to
the assessment of inflammatory phenotypes of steroid-
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clinical data with inflammatory patterns in exhaled breath
and peripheral blood in order to accurately assess paediat-
ric asthma phenotypes related to asthma control, thereby
gaining more insight into the underlying inflammatory
mechanisms.
Many recent studies have focused on improving response
to asthma medication using inflammatory or genetic
markers; so far, success has been limited. Asthma is a het-
erogeneous disease and individual corticosteroid respon-
siveness is mostly likely to be the sum of various factors,
including adherence to treatment, absence or presence of
co-morbidities, exposure to allergens, genetic variations in
therapeutic targets or pathways, as well as inflammatory
patterns that may be intrinsically more or less sensitive to
corticosteroid treatment [5]. All these different factors have
to be taken into account for optimal guidance of individual
treatment. Therefore, accurate phenotyping of children
with asthma is paramount.
In 2009, the PACMAN cohort study was started in
order to assess the effectiveness of asthma medication in
children and the influence of genetic factors [15]. This
resulted in a unique, pharmacy-based paediatric cohort
representing a cross-section of children who use asthma
medication on a regular basis. The asthma phenotypes
ranged from controlled to uncontrolled asthma and from
patients with mild disease primarily treated by general
practitioners to patients with moderate to severe disease
receiving specialized care from paediatricians or paediatric
pulmonologists. The added value of the PACMAN cohort
over that of other existing population-based asthma
cohorts is its primary focus on medication use, in contrast
to other paediatric asthma cohorts that have mainly con-
centrated on determinants of asthma susceptibility or re-
spiratory symptoms [42-44]. Furthermore, large studies
that have assessed treatment effectiveness in asthmatic
children, such as the Childhood Asthma Management
Program (CAMP) [45] or the BREATHE study [46] have
not taken underlying inflammatory patterns into account.
Defining appropriate therapy responses for asthma is a
complex issue because of the heterogeneity of the dis-
ease. Various outcomes have been used to study the
effectiveness of asthma therapies, for example improve-
ment in lung function, symptoms scores or exacerba-
tions (frequently defined by asthma-related hospital
admissions, ER visits and/or oral corticosteroid use). Yet
it is important to realize that predictors of treatment re-
sponse depend upon the chosen definition of outcome
variables [47,48]. Work by Haldar et al. showed that dis-
tinct clusters of adult asthmatics can be identified when
studying two distinct dimensions of disease, i.e. asthma
symptoms and eosinophilic inflammation [2]. These
clusters can be concordant (asthmatic symptoms and
measures of inflammation correlate) or discordant(asthmatic symptoms and measures of inflammation do
not correlate). Others have described distinct inflamma-
tory phenotypes based on sputum profiles of asthmatics
[9,10], indicating that defining outcomes solely on the
presence or absence of symptoms or solely on markers
of (eosinophilic) inflammation may only be informative
for a subgroup of the total patient population. Therefore,
in PACMAN2, we aim to collect data on symptoms as
well as on inflammation markers.
During the first phase of the PACMAN study we
obtained saliva samples for DNA extraction from our
participants. To date, enough saliva has been collected for
sufficient DNA isolation in 74% of the children (550/744).
Recently, we replicated the genetic association identified
by Tantisira et al. between the FCER2 T22026 gene vari-
ant and treatment response in asthmatic children and
showed that this SNP is associated with an increased risk
of asthma-related hospital visits in our population [7,8].
The follow-up of specific subsets in PACMAN2 will give
us the opportunity to identify new pharmacogenetic
targets using proteomic and cellular profiling strategies
and to validate these in the PACMAN cohort.
Markers in exhaled breath, FeNO and VOCs, will also
be measured in an attempt to further elucidate their ap-
plicability in identifying asthma phenotypes in children;
however the direct correlation between FeNO and airway
inflammation remains unclear. FeNO is thought to be a
marker of eosinophilic airway inflammation, but various
other factors including steroid use and atopy seem to sig-
nificantly influence FeNO levels [49]. Several studies have
reported that high levels of FeNO in asthmatics are associ-
ated with a better response to ICS [50-52].
Measuring patterns of VOCs in exhaled breath is a rela-
tively novel metabolomic approach to study molecular sig-
natures of respiratory disease. Exhaled breath contains a
complex mixture of up to thousands of VOCs. These
compounds are produced due to metabolic processes and
the concentrations are likely to be influenced by the pres-
ence of airway inflammation. An electronic nose assesses
the spectrum of volatiles present in exhaled breath with-
out determining the individual molecular components
[53,54]. Previous studies have shown that measurements
of patterns of VOCs (‘breathprints’) using an electronic
nose could discriminate adults with asthma from non-
asthmatic controls [55] and asthmatic patients from
COPD patients [36,56]. Furthermore, a recent study
showed that breathprints of COPD patients with mild dis-
ease correlate well with the activation status of eosinophils
and neutrophils in induced sputum samples of these pa-
tients [57], suggesting that the electronic nose might be
promising non-invasive diagnostic tool to assess ongoing
airway inflammation.
An important strength of PACMAN2 is the extensive
phenotyping of steroid-treated asthmatic children and the
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medication use, adherence and FeNO levels in children
who were long-term, uncontrolled or controlled at the
baseline visit. Nonetheless, due to the fact that the defin-
ition of long-term asthma control will be based upon
retrospective questionnaire data, with parents and chil-
dren being asked to answer questions about asthma symp-
toms over the past four seasons, recall bias may occur
leading to an over- or underestimation of the symptoms,
constituting a potential limitation of our approach. Even
so, long-term asthma control will likely provide additional
information compared to current asthma control solely
and findings from PACMAN2 will provide a better under-
standing of inflammatory phenotypes that may underlie
uncontrolled asthma in inhaled steroid-treated children.
Childhood asthma affects millions of children world-
wide and it is the leading cause of emergency room visits
and hospitalizations in children, resulting in increased
healthcare resources utilization and expenditures, and
ultimately, costs to society. A substantial proportion of
these asthma-related hospital visits occur despite high
dosages of corticosteroid treatment. The identification of
(inflammatory) phenotypes that reflect the pathobiological
mechanisms underlying poor corticosteroid response may
be of great importance in identifying high-risk patients at
an early stage. Results from the PACMAN2 study might
eventually lead to a more individualized treatment ap-
proach for asthmatic children, as well as to the discovery
of new leads for innovative therapeutic strategies.
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